1. Chronic systemic hypoxia promotes LNCaP prostate cancer growth in vivo
- Author
-
Laura Terraneo, Raffaella Ronchi, Paola Bianciardi, Michele Samaja, and Anna Caretti
- Subjects
Male ,Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,Urology ,Blotting, Western ,Transplantation, Heterologous ,Mice, Nude ,Neovascularization ,Hemoglobins ,Mice ,Prostate cancer ,chemistry.chemical_compound ,In vivo ,Cell Line, Tumor ,Internal medicine ,LNCaP ,medicine ,Animals ,Humans ,Phosphorylation ,Protein kinase B ,business.industry ,Body Weight ,Prostatic Neoplasms ,Hypoxia (medical) ,Hypoxia-Inducible Factor 1, alpha Subunit ,medicine.disease ,Immunohistochemistry ,Cell Hypoxia ,Oxygen ,Vascular endothelial growth factor ,Transplantation ,Endocrinology ,Oncology ,chemistry ,medicine.symptom ,business ,Proto-Oncogene Proteins c-akt ,Signal Transduction - Abstract
OBJECTIVE Solid tumors contain underperfused regions where hypoxia-inducible factor-1α (HIF-1α) over-expression induces hypoxia adaptation and cell proliferation. We test the hypothesis that systemic hypoxia promotes prostate cancer growth in vivo and examine HIF-1α centrality in this effect. METHODS Male athymic mice were xenografted with 3 × 106 LNCaP cells per each flank and exposed for 28 days to either chronic hypoxia (CH, 10% O2) or CH with reoxygenation (CHReox, 3 times/week for 1 hr), with normoxia as control (n = 17, 9, and 20, respectively). At the end of the observation, mice were euthanized and tumors harvested for analyses. RESULTS The successful xenografts grew faster in CH and CHReox than in normoxia (first-order rate constants 0.15 ± 0.01, 0.18 ± 0.03, and 0.09 ± 0.01 day−1, P
- Published
- 2010
- Full Text
- View/download PDF